The rapid expansion of biologics, biosimilars, vaccines, monoclonal antibodies, and cell and gene therapies is transforming the pharmaceutical industry. As these complex therapies move through research, development, manufacturing, and commercialization, comprehensive safety testing has become essential to ensure product quality, patient safety, and regulatory compliance.
According to the Biologics Safety Testing Market report by MarketsandMarkets, the global market is projected to grow from USD 5.57 billion in 2026 to USD 9.66 billion by 2031, registering a CAGR of 11.6% during the forecast period.
Download PDF Brochure:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=34624144
Growing Biologics Pipeline Drives Demand for Safety Testing
The expanding biologics and biosimilars pipeline is one of the key factors driving the biologics safety testing market. Unlike many traditional small-molecule drugs, biologics are complex molecules produced through biological processes, making their development and manufacturing more sensitive to contamination and variability.
As pharmaceutical and biotechnology companies increase investments in biologics, they require reliable testing solutions to identify potential contaminants and ensure product quality throughout development and manufacturing.
The expansion of contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs) is also supporting market growth. Increasingly, pharmaceutical companies are outsourcing specialized testing activities to organizations with the required technologies, infrastructure, and regulatory expertise.
Services Segment Dominates the Market
Based on offerings, the market is divided into products and services. The services segment accounted for the largest share of the global biologics safety testing market in 2025.
The dominance of services can be attributed to the increasing complexity of biologics and growing reliance on specialized external testing providers. Pharmaceutical and biotechnology companies are increasingly outsourcing testing activities to CROs and CDMOs to access specialized expertise, advanced analytical capabilities, and established regulatory knowledge.
End-to-end testing services can support biologics development and manufacturing across multiple stages. This becomes particularly important as companies expand their pipelines of monoclonal antibodies, vaccines, therapeutic proteins, and advanced cell and gene therapies.
The growing demand for outsourced testing is therefore expected to remain a significant growth driver throughout the forecast period.
Mycoplasma, Sterility, Endotoxin, and Bioburden Testing Remain Essential
Biologics safety testing encompasses several critical test types, including mycoplasma testing, sterility testing, endotoxin testing, and bioburden testing.
These tests are important for detecting microbial contamination and ensuring that biologic products meet stringent quality and safety requirements.
Mycoplasma testing is particularly important because mycoplasmas can contaminate cell cultures without being easily detected through conventional visual inspection. Sterility testing helps assess whether products are free from viable microorganisms, while endotoxin testing is used to identify potentially harmful bacterial endotoxins.
Bioburden testing, meanwhile, helps quantify viable microorganisms present in materials or products before sterilization or further processing.
As biologics manufacturing becomes more sophisticated, demand for reliable, sensitive, and efficient testing technologies is expected to increase.
Vaccine Safety Testing Expected to Grow Rapidly
Among applications, vaccine safety testing is estimated to be the fastest-growing service application segment during the forecast period.
The expansion of immunization programs and increasing vaccine production are creating additional demand for comprehensive testing solutions. Vaccine manufacturers must meet stringent quality and safety requirements throughout development and production.
The emergence of new vaccine technologies and continued investment in vaccine development are further expanding opportunities for safety testing providers. Regulatory requirements related to batch release, contamination control, and quality assurance are also contributing to demand.
As global healthcare systems continue strengthening vaccination programs, vaccine safety testing is expected to remain an important growth area.
Cell and Gene Therapies Create New Testing Requirements
The rapid development of cell and gene therapies (CGT) is creating new opportunities within the biologics safety testing industry. These therapies involve complex biological materials and manufacturing processes, requiring specialized approaches to quality and safety assessment.
As more cell and gene therapy candidates progress through clinical development and commercialization, manufacturers and testing providers are developing capabilities to address the unique testing requirements associated with these products.
The expansion of CGT manufacturing, combined with increased investment in advanced therapies, is expected to support demand for specialized safety testing services.
North America Maintains Market Leadership
North America accounted for the largest regional share of the global biologics safety testing market in 2025. The region benefits from a high concentration of biopharmaceutical companies, advanced research infrastructure, strong regulatory oversight, and a well-established clinical research ecosystem.
The US remains a major hub for biologics development and manufacturing. The presence of the FDA and stringent regulatory requirements supports demand for comprehensive safety and quality testing.
The rapid adoption of cell and gene therapies is another important growth factor. As advanced therapies move toward commercialization, manufacturers require specialized testing capabilities to meet regulatory and quality requirements.
Furthermore, strong public and private investment in biotechnology and widespread outsourcing to CROs and CDMOs continue to strengthen North America’s position in the global market.
Outsourcing Reshapes the Biologics Safety Testing Landscape
Outsourcing has become increasingly important as biologics development becomes more complex. Pharmaceutical and biotechnology companies can work with specialized testing providers to access advanced analytical platforms and scientific expertise without having to build every capability internally.
CROs and CDMOs are therefore becoming important partners across biologics development and manufacturing. Their ability to provide testing services across multiple stages can help companies manage increasingly demanding development requirements.
This trend is expected to remain particularly relevant as smaller biotechnology companies expand their pipelines and larger pharmaceutical companies seek greater flexibility in managing complex manufacturing and testing programs.
Competitive Landscape
The biologics safety testing market includes major life sciences, pharmaceutical services, and analytical technology companies. Prominent players include Thermo Fisher Scientific, Merck KGaA, Lonza, FUJIFILM Corporation, Sartorius, F. Hoffmann-La Roche, Charles River Laboratories, bioMérieux, Maravai LifeSciences, WuXi AppTec, SGS, Sotera Health, Samsung Biologics, GenScript, Agilent Technologies, Syngene International, Eurofins Scientific, Labcorp, Bio-Rad Laboratories, and QIAGEN.
These companies are focusing on service expansion, technological innovation, strategic collaborations, geographic expansion, and advanced testing capabilities to address the evolving requirements of biologics manufacturers.
Future Outlook for Biologics Safety Testing
The future of the biologics safety testing market will be closely linked to the continued growth of biologics, biosimilars, vaccines, monoclonal antibodies, and cell and gene therapies. As these products become more complex, manufacturers will require increasingly sophisticated testing solutions to maintain safety and quality.
The market’s projected growth from USD 5.57 billion in 2026 to USD 9.66 billion by 2031 highlights the expanding importance of safety testing across the biologics value chain.
With the services segment maintaining market leadership, vaccine safety testing emerging as a high-growth application, and North America retaining its dominant regional position, the industry is moving toward increasingly specialized and outsourced testing models.
Ultimately, advances in biologics manufacturing, growing regulatory expectations, and the expansion of next-generation therapies will continue to make safety testing a critical component of modern biopharmaceutical development.
Request Sample Pages:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=34624144